​

1. Al-Shaibi S, Abushanab D, Abounahia F, Awaisu A, Al-Badriyeh D. Letter to Editor on Fawad et al. Comment on "Cost-Effectiveness Analysis of Ibuprofen versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates" by Al-Shaibi et al. Curr Probl Cardiol. 2024 Jan;49(1 Pt C):102157. doi: 10.1016/j.cpcardiol.2023.102157. Epub 2023 Oct 18. PMID: 37858850.
2. Abushanab D, Atchan M, Elajez R, Elshafei M, Abdelbari A, Al Hail M, Abdulrouf PV, El-Kassem W, Ademi Z, Fadul A, Abdalla E, Diab MI, Al-Badriyeh D. Economic impact of clinical pharmacist interventions in a general tertiary hospital in Qatar. PLoS One. 2023 Jun 1;18(6):e0286419. doi: 10.1371/journal.pone.0286419. PMID: 37262042; PMCID: PMC10234553.
3. Abushanab D, Al-Badriyeh D, Marquina C, Liew D, Al-Zaidan M, Ghaith Al-Kuwari M, Abdulmajeed J, Ademi Z. Societal health and economic burden of cardiovascular diseases in the population with type 2 diabetes in Qatar. A 10-year forecasting model. Diabetes Obes Metab. 2024 Jan;26(1):148-159. doi: 10.1111/dom.15299. Epub 2023 Oct 16. PMID: 37845584.
4. Al-Badriyeh D, Kaddoura R, AlMaraghi F, Homosy A, Hail MA, El-Kassem W, Rouf PVA, Fadul A, Mahfouz A, Alyafei SA, Abushanab D. Impact of Clinical Pharmacist Interventions on Economic Outcomes in a Cardiology Setting in Qatar. Curr Probl Cardiol. 2023 Sep;48(9):101838. doi: 10.1016/j.cpcardiol.2023.101838. Epub 2023 May 25. PMID: 37244514.
5. Al-Shaibi S, Abushanab D, Abounahia F, Awaisu A, Al-Badriyeh D. Cost-Effectiveness Analysis of Ibuprofen Versus Indomethacin or Paracetamol for the Treatment of Patent Ductus Arteriosus in Preterm Neonates. Curr Probl Cardiol. 2023 Sep;48(9):101751. doi: 10.1016/j.cpcardiol.2023.101751. Epub 2023 Apr 21. PMID: 37088173.
6. Abushanab D, Gulied A, Hamad A, Abu-Tineh M, Abdul Rouf PV, Al Hail M, El-Kassem W, El Hajj MS, Al-Badriyeh D. Cost savings and cost avoidance with the inpatient clinical pharmacist interventions in a tertiary cancer care hospital. J Oncol Pharm Pract. 2023 Dec;29(8):1935-1943. doi: 10.1177/10781552231160275. Epub 2023 Mar 22. PMID: 36946146.
7. Hamad A, Elazzazy S, Bujassoum S, Rasul K, Gaziev J, Cherif H, Al-Boloshi Z, Hanssens Y, Saleh A, Rasheed HA, Al-Badriyeh D, Babiker A, Hmaidan AA, Al-Hail M. Applying value-based strategies to accelerate access to novel cancer medications: guidance from the Oncology Health Economics Expert Panel in Qatar (Q-OHEP). BMC Health Serv Res. 2023 Jan 6;23(1):15. doi: 10.1186/s12913-022-08981-5. PMID: 36609388; PMCID: PMC9816531.
8. Al-Badriyeh D, Hssain AA, Abushanab D. Cost-Effectiveness Analysis of Out-Of-Hospital versus In-Hospital Extracorporeal Cardiopulmonary Resuscitation for Out-Hospital Refractory Cardiac Arrest. Curr Probl Cardiol. 2022 Dec;47(12):101387. doi: 10.1016/j.cpcardiol.2022.101387. Epub 2022 Sep 5. PMID: 36070844.
9. Kaddoura R, Abushanab D, Arabi AR, Alyafei SA, Al-Badriyeh D. Cost-Effectiveness Analysis of Sacubitril/Valsartan for Reducing the Use of Implantable Cardioverter-Defibrillator (ICD) and the Risk of Death in ICD-Eligible Heart Failure Patients with Reduced Ejection Fraction. Curr Probl Cardiol. 2022 Dec;47(12):101385. doi: 10.1016/j.cpcardiol.2022.101385. Epub 2022 Sep 5. PMID: 36063914.
10. Pathadka S, Yan VKC, Neoh CF, Al-Badriyeh D, Kong DCM, Slavin MA, Cowling BJ, Hung IFN, Wong ICK, Chan EW. Global Consumption Trend of Antifungal Agents in Humans From 2008 to 2018: Data From 65 Middle- and High-Income Countries. Drugs. 2022 Jul;82(11):1193-1205. doi: 10.1007/s40265-022-01751-x. Epub 2022 Aug 12. PMID: 35960433; PMCID: PMC9402496.
11. Abushanab D, Al-Badriyeh D, Marquina C, Bailey C, Jaam M, Liew D, Ademi Z. A Systematic Review of Cost-Effectiveness of Non-Statin Lipid-Lowering Drugs for Primary and Secondary Prevention of Cardiovascular Disease in Patients with Type 2 Diabetes Mellitus. Curr Probl Cardiol. 2023 Aug;48(8):101211. doi: 10.1016/j.cpcardiol.2022.101211. Epub 2022 Apr 20. PMID: 35460688.
12. Abushanab D, Eldebs M, Basha A, Naseralallah L, Kazkaz H, Moursi A, Albazoon F, Wafi O, Badran S, Doi SAR, Al-Maadeed S, Alam MF, Al-Badriyeh D. The Economic Impact of Optimizing a COVID-19 Management Protocol in Pre-Existing Cardiovascular Disease Patients. Curr Probl Cardiol. 2023 Aug;48(8):101177. doi: 10.1016/j.cpcardiol.2022.101177. Epub 2022 Mar 25. PMID: 35341802; PMCID: PMC8950076.
13. Eljilany I, Elewa H, Al-Badriyeh D. Cost-Benefit Analysis of Genotype-Guided Interruption Days in Warfarin Pre-Procedural Management. Curr Probl Cardiol. 2023 Jun;48(6):101128. doi: 10.1016/j.cpcardiol.2022.101128. Epub 2022 Jan 31. PMID: 35114296.
14. Abushanab D, Al-Badriyeh D, Liew D, Ademi Z. First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis. Curr Probl Cardiol. 2022 Jun;47(6):100852. doi: 10.1016/j.cpcardiol.2021.100852. Epub 2021 Apr 6. PMID: 33992426.